A Phase 3 interventional study of Cariprazine in Schizophrenia, sponsored by Forest Laboratories. Completed at 86 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-07-26.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one is the 2nd largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 3, and was the 6th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 3 started in 2010.
This study's enrollment of 752 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
27 studies in Schizophrenia by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 26 finished, 11 (42%) have results posted.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 2nd largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 3, and was the 9th registered.
AbbVie’s Schizophrenia studies by the year they started, since 2004.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 27 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.
Drug: Cariprazine
Cariprazine was supplied in capsules.
Also known as: RGH-188
Change From Baseline to Week 48 in the PANSS Total Score
The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.
Time frame: Baseline to Week 48
Change From Baseline to Week 48 in the CGI-S Score
The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.
Time frame: Baseline to Week 48
| Milestone | Cariprazine |
|---|---|
| Started | 752 |
| Completed | 226 |
| Not completed | 526 |
| Withdrew: Adverse event | 77 |
| Withdrew: Insufficient therapeutic response | 22 |
| Withdrew: Protocol violation | 45 |
| Withdrew: Withdrawal of consent | 179 |
| Withdrew: Lost to follow-up | 43 |
| Withdrew: Reasons not specified | 27 |
| Withdrew: Did not meet eligibility criteria | 133 |
The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.
| Units on a scale | Cariprazine |
|---|---|
| Baseline | 66.5 ± 12.1 |
| Change From Baseline | -5.0 ± 14.0 |
The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.
| Units on a scale | Cariprazine |
|---|---|
| Baseline | 3.0 ± 0.4 |
| Change From Baseline | -0.1 ± 0.8 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cariprazine | 0/586 (0%) | 59/586 (10.1%) | 419/586 (71.5%) |
| Event | Cariprazine |
|---|---|
| SchizophreniaPsychiatric disorders | 25/586 |
| Psychotic disorderPsychiatric disorders | 12/586 |
| Social stay hospitalisationSocial circumstances | 6/586 |
| Suicidal ideationPsychiatric disorders | 4/586 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/178 |
| CellulitisInfections and infestations | 2/586 |
| DepressionPsychiatric disorders | 2/586 |
| Hallucination, auditoryPsychiatric disorders | 2/586 |
| Schizophrenia, paranoid typePsychiatric disorders | 2/586 |
| Autoimmune thrombocytopeniaBlood and lymphatic system disorders | 1/586 |
| Event | Cariprazine |
|---|---|
| AkathisiaNervous system disorders | 118/586 |
| HeadacheNervous system disorders | 104/586 |
| InsomniaPsychiatric disorders | 104/586 |
| Weight increasedInvestigations | 79/586 |
| AnxietyPsychiatric disorders | 68/586 |
| NauseaGastrointestinal disorders | 51/586 |
| RestlessnessPsychiatric disorders | 49/586 |
| Extrapyramidal disorderNervous system disorders | 47/586 |
| TremorNervous system disorders | 46/586 |
| DyspepsiaGastrointestinal disorders | 42/586 |
The flexible-dose design for this study was selected to examine the relative safety and tolerability of a range of dosages of cariprazine. The starting dose of 1.5 mg/day was titrated as needed within the range of 3.0 - 9.0 mg/day based on the Investigator's judgment of response and tolerability.
| Age, Continuous(years) | Cariprazine |
|---|---|
| Mean | 39.1 ± 10.8 |
| Sex: Female, Male(Participants) | Cariprazine |
|---|---|
| Female | 178 |
| Male | 408 |
| Ethnicity (NIH/OMB)(Participants) | Cariprazine |
|---|---|
| Hispanic or Latino | 48 |
| Not Hispanic or Latino | 523 |
| Unknown or Not Reported | 15 |
| Race (NIH/OMB)(Participants) | Cariprazine |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 68 |
| Native Hawaiian or Other Pacific Islander | 3 |
| Black or African American | 229 |
| White | 250 |
| More than one race | 0 |
| Unknown or Not Reported | 35 |
| Weight(kg) | Cariprazine |
|---|---|
| Mean | 79.94 ± 20.26 |
| Body Mass Index (BMI)(kg/m^2) | Cariprazine |
|---|---|
| Mean | 27.10 ± 5.80 |
| Waist circumference(cm) | Cariprazine |
|---|---|
| Mean | 91.76 ± 15.85 |
Ran from May 2010 to primary completion in Jan 2013, 32 months.
Results were first posted in Jul 2019, 6 years 5 months after primary completion. A results delay was requested in Mar 2014.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 32 months is close to that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine